PUBLISHER: The Business Research Company | PRODUCT CODE: 1938713
PUBLISHER: The Business Research Company | PRODUCT CODE: 1938713
Veterinary biologics encompass biological products obtained from living organisms such as viruses, bacteria, or other microorganisms. These specialized products in veterinary medicine serve to prevent, diagnose, or treat diseases in animals.
Key products falling under veterinary biologics include vaccines, diagnostic kits, immunomodulators, antiserums, antibodies, and related items. Vaccines, for instance, are formulated to trigger the immune system's response and offer protection against specific animal diseases. They address various ailments such as bluetongue, foot and mouth disease, brucellosis, tuberculosis, and others. These products are distributed through multiple channels, including veterinary hospitals and clinics, for diverse applications involving both production and companion animals.
Tariffs have impacted the veterinary biologics market by increasing the cost of imported vaccines, diagnostic kits, and immunomodulators, leading to supply chain disruptions in regions such as North America and Europe. Production animal biologics and high-value companion animal products are the most affected segments. While tariffs have raised costs, they have also encouraged local manufacturing and innovation in biologics production, helping regional companies expand capabilities and reduce dependency on imports.
The veterinary biologics market research report is one of a series of new reports from The Business Research Company that provides veterinary biologics market statistics, including veterinary biologics industry global market size, regional shares, competitors with a veterinary biologics market share, detailed veterinary biologics market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary biologics industry. This veterinary biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The veterinary biologics market size has grown strongly in recent years. It will grow from $13.61 billion in 2025 to $14.61 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to growing prevalence of livestock diseases, rise in companion animal population, advancements in vaccine development, increased government funding for veterinary research, expansion of veterinary healthcare infrastructure.
The veterinary biologics market size is expected to see strong growth in the next few years. It will grow to $20.03 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to technological advancements in biologics, increasing adoption of precision medicine in animals, rise in global pet ownership, growing awareness about zoonotic diseases, expansion of veterinary diagnostics market. Major trends in the forecast period include increased focus on preventive animal healthcare, growing adoption of rapid diagnostic solutions, expansion of companion animal biologics, integration of immunomodulators in veterinary treatments, rising demand for livestock disease management solutions.
The growing adoption of pets is expected to drive the growth of the veterinary biologics market in the coming years. Pet adoption involves taking responsibility for a domesticated animal, often from a shelter or rescue organization, and providing it with a permanent and caring home. The adoption of pets is increasing due to greater awareness of animal welfare, as more individuals recognize the advantages of adopting rescued animals and increasingly choose adoption over purchasing pets. Veterinary biologics help prevent a wide range of infectious diseases in pets, provide immunity, control zoonotic diseases, improve lifespan and quality of life, reduce veterinary healthcare costs, enhance reproductive health, and enable more targeted and customized treatment options. For example, in March 2025, the American Pet Products Association, a US-based non-profit organization, reported that 94 million US households owned at least one pet, compared with 82 million households in 2023. Therefore, the rising adoption of pets is contributing to the growth of the veterinary biologics market.
Leading companies in the veterinary biologics market are concentrating on the development of innovative biologics, such as vaccines, to improve animal health and prevent diseases. A vaccine is a substance that triggers the immune system to recognize and combat specific pathogens, helping to prevent infectious diseases by providing acquired immunity. For example, in August 2024, Merck Animal Health, a global animal health company based in the U.S., launched an experimental autogenous vaccine targeting avian metapneumovirus (aMPV) type B, which received approval from the U.S. Department of Agriculture (USDA) for manufacturing and sale. Created in partnership with Cambridge Technologies, this vaccine aims to address the serious respiratory problems caused by aMPV type B in poultry, which have resulted in significant economic losses since late 2023. Manufactured at a state-of-the-art facility in Minnesota, the vaccine uses an oil and water emulsion formulation designed to reduce post-vaccination tissue reactions, filling a crucial gap in the market as there were previously no commercially licensed vaccines available.
In January 2024, Ceva Sante Animale, a pharmaceutical company based in France, acquired Scout Bio for an undisclosed amount. This acquisition enhances Ceva's biotechnology capabilities and speeds up its innovation in pet therapeutics, particularly targeting advanced treatments for chronic diseases. This strategic move responds to the growing demand for better health solutions among pet owners. Scout Bio is a biotechnology company located in the U.S. that specializes in providing essential data for the development of effective veterinary biologics, including vaccines and diagnostics.
Major companies operating in the veterinary biologics market are Zoetis Inc., Merck Animal Health Inc., Boehringer Ingelheim Animal Health Inc., Elanco Animal Health, IDEXX Laboratories Inc., Virbac SA, Phibro Animal Health Corporation, Abaxis Inc., Bimeda Biologicals, Ceva Sante Animale S.A., Heska Corporation, Colorado Serum Company, Hester Biosciences Limited, INDICAL Bioscience GmbH, Intervet Inc., Hebei Veyong Animal Pharmaceutical Co. Ltd., Biomet Biologics LLC, CytoDyn Veterinary Medicine LLC, KM Biologics, HIPRA, Indian Immunologicals Ltd., Vetoquinol, Beijing SVA Vaccines Serums
North America was the largest region in the veterinary biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the veterinary biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The veterinary biologics market consists of sales of transplant tissues, recombinant proteins, and stem cells. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Veterinary Biologics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses veterinary biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for veterinary biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The veterinary biologics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.